Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
  • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
  • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
  • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
  • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• lipids and/or lipids compositions that can deliver nucleic acids, such as short interfering RNA (siRNA) and messenger RNA (mRNA) with high efficiency and low toxicity.
• siRNA short interfering RNA
• mRNA messenger RNA
• compositions comprising stereochemically enriched lipids for delivering mRNA are highly effective and have unexpectedly low toxicity in delivering mRNA and producing encoded protein in vivo:
• stereochemically enriched compositions of I have surprisingly low toxicity compared to stereochemically non-enriched, or stereochemically less enriched, compositions of the same lipid, as evidenced, for example, by the dramatically lower alanine aminotransferase (ALT) and aspartate aminotransferase (AST) expression levels. See Table 1.
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• compositions characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La, I.b.l, I.b.2, 1.c, I.d, I.e, I.f, I.g, or I.h, each of which is independently as defined and described below.
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• the first threshold amount is 50%;
• the first threshold amount is 25%;
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• the first threshold amount is 6.25%
• the first threshold amount is 6.25%
• first threshold amount is 12.5%; or are chemical entities of formula I.h:
• the first threshold amount is 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In some embodiments, the first threshold amount is 50%. In some embodiments, the first threshold amount is 70%. In some embodiments, the first threshold amount is 80%. In some embodiments, the first threshold amount is 95%>.
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• compositions characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of a first formula selected from formulae La, I.b.l, I.b.2, 1.c, I.d, I.e, I.f, I.g, or Lh; and
• greater than or equal to a second threshold amount of the total amount of the chemical entities of the first formula in the composition are chemical entities of the same stereoisomer of the first formula.
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition is a chemical entity of formula La.i:
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition is a chemical entity of formula La.ii:
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula Lb.l.
• a second threshold amount of the total amount of chemical entities of formula Lb.l in the composition is a chemical entity of formula Lb.l.i:
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.l in the composition is a chemical entity of formula Lb.l.ii:
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.2 in the composition is a chemical entity of formula I.b.2.i:
• a second threshold amount of the total amount of chemical entities of formula I.b.2 in the composition is a chemical entity of formula I.b.2.ii:
• the second threshold amount is 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In some embodiments, the second threshold amount is 50%. In some embodiments, the second threshold amount is 70%. In some embodiments, the second threshold amount is 80%>. In some embodiments, the second threshold amount is 95%>.
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of the same stereoisomer of formula I.
• a stereoisomer of formula I has the structure of formula I.a.i,
• greater than or equal to the third threshold amount of the total amount of the composition is a chemical entity of formula I.a.i, I.a.ii, I.b.l.i, I.b.l.ii, I.b.2.i, or I.b.2.ii.
• greater than or equal to the third threshold amount of the total amount of the composition is a chemical entity of formula I.a.i.
• greater than or equal to the third threshold amount of the total amount of the composition is a chemical entity of formula I.a.ii.
• greater than or equal to the third threshold amount of the total amount of the composition is a chemical entity of formula I.b.l.i.
• greater than or equal to the third threshold amount of the total amount of the composition is a chemical entity of formula I.b.l.ii. In some embodiments, greater than or equal to the third threshold amount of the total amount of the composition is a chemical entity of formula I.b.2.i. In some embodiments, greater than or equal to the third threshold amount of the total amount of the composition is a chemical entity of formula I.b.2.ii.
• the third threshold amount is 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% (w/w). In some embodiments, the third threshold amount is 50% (w/w). In some embodiments, the third threshold amount is 70% (w/w). In some embodiments, the third threshold amount is 80%> (w/w). In some embodiments, the third threshold amount is 85% (w/w). In some embodiments, the third threshold amount is 95% (w/w).
• a provided composition further comprises one or more mR A for mRNA delivery and expression of the encoded protein in vivo.
• the present invention provides methods for highly efficient delivery and expression of mRNA and encoded protein in vivo.
• the present invention provides a method of delivery of mRNA in vivo, comprising administering to a subject in need of delivery a provided composition which comprises an mRNA.
• a provide composition permits more delivered mRNA, higher protein expression level and/or lower administration frequency, thereby providing a more potent, safer, and more patent- friendly mRNA therapy.
• FIG. 1 depicts the results of in vivo human ASS1 protein production in wild type mouse liver upon treatment with lipid nanoparticles that include compounds of formula I.
• amino acid in its broadest sense, refers to any compound and/or substance that can be incorporated into a polypeptide chain.
• an amino acid has the general structure H E N-C(H)(R)-COHO.
• an amino acid is a naturally occurring amino acid.
• an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a d-amino acid; in some embodiments, an amino acid is an 1-amino acid.
• Standard amino acid refers to any of the twenty standard 1-amino acids commonly found in naturally occurring peptides.
• Nonstandard amino acid refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source.
• synthetic amino acid encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and/or substitutions.
• Amino acids, including carboxyl- and/or amino-terminal amino acids in peptides, can be modified by methylation, amidation, acetylation, protecting groups, and/or substitution with other chemical groups that can change the peptide's circulating half-life without adversely affecting their activity. Amino acids may participate in a disulfide bond.
• Amino acids may comprise one or posttranslational modifications, such as association with one or more chemical entities (e.g., methyl groups, acetate groups, acetyl groups, phosphate groups, formyl moieties, isoprenoid groups, sulfate groups, polyethylene glycol moieties, lipid moieties, carbohydrate moieties, biotin moieties, etc.).
• chemical entities e.g., methyl groups, acetate groups, acetyl groups, phosphate groups, formyl moieties, isoprenoid groups, sulfate groups, polyethylene glycol moieties, lipid moieties, carbohydrate moieties, biotin moieties, etc.
• amino acid is used interchangeably with "amino acid residue,” and may refer to a free amino acid and/or to an amino acid residue of a peptide. It will be apparent from the context in which the term is used whether it refers to a free amino acid or a residue of a
• animal refers to any member of the animal kingdom. In some embodiments, “animal” refers to humans, at any stage of development. In some embodiments, “animal” refers to non-human animals, at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g. , a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and/or worms. In some embodiments, an animal may be a transgenic animal, genetically-engineered animal, and/or a clone.
• mammal e.g. , a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a
• Chemical entity As used herein, the term “chemical entity” includes a compound, salt, or solvate thereof, or any combination of compounds, salts, or solvates thereof.
• delivery encompasses both local and systemic delivery.
• delivery of mR A encompasses situations in which an mRNA is delivered to a target tissue and the encoded protein is expressed and retained within the target tissue (also referred to as “local distribution” or “local delivery”), and situations in which an mRNA is delivered to a target tissue and the encoded protein is expressed and secreted into patient's circulation system (e.g., serum) and systematically distributed and taken up by other tissues (also referred to as “systemic distribution” or “systemic delivery).
• patient's circulation system e.g., serum
• expression refers to translation of an mRNA into a polypeptide, assemble multiple polypeptides (e.g., heavy chain or light chain of antibody) into an intact protein (e.g., antibody) and/or post-translational modification of a polypeptide or fully assembled protein (e.g., antibody).
• expression and “production,” and grammatical equivalent, are used inter-changeably.
• a "functional" biological molecule is a biological molecule in a form in which it exhibits a property and/or activity by which it is characterized.
• Half-life As used herein, the term "half-life" is the time required for a quantity such as nucleic acid or protein concentration or activity to fall to half of its value as measured at the beginning of a time period.
• improve As used herein, the terms “improve,” “increase” or “reduce,” or grammatical equivalents, indicate values that are relative to a baseline measurement, such as a measurement in the same individual prior to initiation of the treatment described herein, or a measurement in a control subject (or multiple control subject) in the absence of the treatment described herein.
• a “control subject” is a subject afflicted with the same form of disease as the subject being treated, who is about the same age as the subject being treated.
• in vitro refers to events that occur in an artificial environment, e.g. , in a test tube or reaction vessel, in cell culture, etc. , rather than within a multicellular organism.
• in vivo refers to events that occur within a multicellular organism, such as a human and a non-human animal. In the context of cell-based systems, the term may be used to refer to events that occur within a living cell (as opposed to, for example, in vitro systems).
• Isolated refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities may be separated from about 10%, about 20%, about 30%>, about 40%>, about 50%>, about 60%>, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%o, about 97%), about 98%>, about 99%, or more than about 99% of the other components with which they were initially associated.
• isolated agents are about 80%>, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%), about 98%>, about 99%, or more than about 99% pure.
• a substance is "pure” if it is substantially free of other components.
• calculation of percent purity of isolated substances and/or entities should not include excipients (e.g., buffer, solvent, water, etc.).
• Local distribution or delivery As used herein, the terms “local distribution,” “local delivery,” or grammatical equivalent, refer to tissue specific delivery or distribution. Typically, local distribution or delivery requires a protein (e.g., enzyme) encoded by mRNAs be translated and expressed intracellularly or with limited secretion that avoids entering the patient's circulation system.
• a protein e.g., enzyme
• messenger RNA As used herein, the term "messenger RNA (mRNA)" refers to a polynucleotide that encodes at least one polypeptide. mRNA as used herein encompasses both modified and unmodified RNA. mRNA may contain one or more coding and non-coding regions. mRNA can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, mRNA can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, backbone modifications, etc. An mRNA sequence is presented in the 5' to 3' direction unless otherwise indicated.
• an mRNA is or comprises natural nucleosides ⁇ e.g., adenosine, guanosine, cytidine, uridine); nucleoside analogs ⁇ e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3- methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2- aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5- propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)
• the mRNA comprises one or more nonstandard nucleotide residues.
• the nonstandard nucleotide residues may include, e.g., 5-methyl-cytidine ("5mC"), pseudouridine, and/or 2-thio-uridine (“2sU”). See, e.g., U.S. Patent No. 8,278,036 or WO2011012316 for a discussion of such residues and their incorporation into mRNA.
• the mRNA may be RNA, which is defined as RNA in which 25% of U residues are 2-thio-uridine and 25% of C residues are 5-methylcytidine.
• RNA is disclosed US Patent Publication US20120195936 and internation publication WO2011012316, both of which are hereby incorporated by reference in their entirety.
• the presence of nonstandard nucleotide residues may render an mRNA more stable and/or less immunogenic than a control mRNA with the same sequence but containing only standard residues.
• the mRNA may comprise one or more nonstandard nucleotide residues chosen from isocytosine, pseudoisocytosine, 5-bromouracil, 5-propynyluracil, 6-aminopurine, 2-aminopurine, inosine, diaminopurine and 2-chloro-6-aminopurine cytosine, as well as combinations of these modifications and other nucleobase modifications.
• Certain embodiments may further include additional modifications to the furanose ring or nucleobase. Additional modifications may include, for example, sugar modifications or substitutions (e.g., one or more of a 2'-0-alkyl modification, a locked nucleic acid (UNA)).
• the RNAs may be complexed or hybridized with additional polynucleotides and/or peptide polynucleotides (PNA).
• PNA polynucleotides and/or peptide polynucleotides
• the sugar modification is a 2'-0-alkyl modification
• such modification may include, but are not limited to a 2'-deoxy-2'-fluoro modification, a 2'-0-methyl modification, a 2'-0-methoxyethyl modification and a 2'-deoxy modification.
• any of these modifications may be present in 0-100% of the nucleotides— for example, more than 0%, 1%, 10%, 25%, 50%, 75%, 85%, 90%, 95%, or 100% of the constituent nucleotides individually or in combination.
• nucleic acid refers to any compound and/or substance that is or can be incorporated into a polynucleotide chain.
• a nucleic acid is a compound and/or substance that is or can be incorporated into a polynucleotide chain via a phosphodiester linkage.
• nucleic acid refers to individual nucleic acid residues (e.g., nucleotides and/or nucleosides).
• nucleic acid refers to a polynucleotide chain comprising individual nucleic acid residues.
• nucleic acid encompasses R A as well as single and/or double-stranded DNA and/or cDNA.
• a patient refers to any organism to which a provided composition may be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes. Typical patients include animals ⁇ e.g., mammals such as mice, rats, rabbits, non-human primates, and/or humans). In some embodiments, a patient is a human. A human includes pre and post natal forms.
• compositions that, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• Polymer refers to a compound comprised of at least 3 (e.g., at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, etc.) repeating covalently bound structural units.
• Salt As used herein, the term “salt” or “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describes
• Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
• suitable inorganic and organic acids and bases include those derived from suitable inorganic and organic acids and bases.
• pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or rnalonic acid or by using other methods used in the art such as ion exchange.
• inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
• organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or rnalonic acid or by using other methods used in the art such as ion exchange.
• pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate,
• benzenesulfonate benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate.
• digluconate dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pival
• Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Cl-4alkyl)4 salts.
• Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
• pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, sulfonate and aryl sulfonate.
• Further pharmaceutically acceptable salts include salts formed from the quarternization of an amine using an appropriate electrophile, e.g., an alkyl halide, to form a quarternized alkylated amino salt.
• Systemic distribution or delivery As used herein, the terms “systemic distribution,” “systemic delivery,” or grammatical equivalent, refer to a delivery or distribution mechanism or approach that affect the entire body or an entire organism. Typically, systemic distribution or delivery is accomplished via body's circulation system, e.g., blood stream. Compared to the definition of "local distribution or delivery.”
• Subject refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate).
• a human includes pre- and post-natal forms.
• a subject is a human being.
• a subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease.
• the term "subject” is used herein interchangeably with “individual” or "patient.”
• a subject can be afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder.
• Target tissues refers to any tissue that is affected by a disease to be treated. In some embodiments, target tissues include those tissues that display disease-associated pathology, symptom, or feature.
• therapeutically effective amount As used herein, the term "therapeutically effective amount" of a therapeutic agent means an amount that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, diagnose, prevent, and/or delay the onset of the symptom(s) of the disease, disorder, and/or condition. It will be appreciated by those of ordinary skill in the art that a therapeutically effective amount is typically administered via a dosing regimen comprising at least one unit dose.
• Treating refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of and/or reduce incidence of one or more symptoms or features of a particular disease, disorder, and/or condition. Treatment may be administered to a subject who does not exhibit signs of a disease and/or exhibits only early signs of the disease for the purpose of decreasing the risk of developing pathology associated with the disease.
• the present invention provides, among other things, lipid compositions and methods for delivering mR A in vivo using stereochemical ⁇ enriched lipid compositions.
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof,
• compositions characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La, I.b.l, I.b.2, 1.c, I.d, I.e, I.f, I.g, or I.h.
• a provided composition is characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La, I.b.l, I.b.2, I.c, I.d, I.e, I.f, I.g, or I.h.
• a provided composition is characterized in that a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La, I.b.l, I.b.2, 1.c, I.d, I.e, I.f, I.g, or I.h.
• a "chemical entity" of a formula is a compound of the formula, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof.
• the first threshold amount is 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In some embodiments, the first threshold amount is 50%. In some embodiments, the first threshold amount is 70%. In some embodiments, the first threshold amount is 80%. In some embodiments, the first threshold amount is 95%>.
• the composition is characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La. In some embodiments, the composition is characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La. In some embodiments, the composition is characterized in that a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La. In some embodiments, a first threshold amount is 50%. In some embodiments, a first threshold amount is 70%. In some embodiments, a first threshold amount is 80%. In some embodiments, a first threshold amount is 90%. In some embodiments, a first threshold amount is 95%.
• the composition is characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.l. In some embodiments, the composition is characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.l. In some embodiments, the composition is characterized in that a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.l. In some embodiments, a first threshold amount is 25%. In some embodiments, a first threshold amount is 50%. In some embodiments, a first threshold amount is 70%. In some embodiments, a first threshold amount is 80%. In some embodiments, a first threshold amount is 90%. In some embodiments, a first threshold amount is 95%.
• the composition is characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.2. In some embodiments, the composition is characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.2. In some embodiments, the composition is characterized in that a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.2. In some embodiments, a first threshold amount is 25%. In some embodiments, a first threshold amount is 50%. In some embodiments, a first threshold amount is 70%. In some embodiments, a first threshold amount is 80%. In some embodiments, a first threshold amount is 90%. In some embodiments, a first threshold amount is 95%.
• the composition is characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.e. In some embodiments, the composition is characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.e. In some embodiments, the composition is characterized in that a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.e. In some embodiments, a first threshold amount is 6.25%. In some embodiments, a first threshold amount is 12.5%. In some embodiments, a first threshold amount is 25%. In some embodiments, a first threshold amount is 50%. In some embodiments, a first threshold amount is 70%. In some embodiments, a first threshold amount is 80%. In some embodiments, a first threshold amount is 90%. In some embodiments, a first threshold amount is 95%.
• the composition is characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.d. In some embodiments, the composition is characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.d. In some embodiments, the composition is characterized in that a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.d. In some embodiments, a first threshold amount is 6.25%. In some embodiments, a first threshold amount is 12.5%. In some embodiments, a first threshold amount is 25%. In some embodiments, a first threshold amount is 50%. In some embodiments, a first threshold amount is 70%. In some embodiments, a first threshold amount is 80%. In some embodiments, a first threshold amount is 90%. In some embodiments, a first threshold amount is 95%.
• the composition is characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.e. In some embodiments, the composition is characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.e. In some embodiments, the composition is characterized in that a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.e. In some embodiments, a first threshold amount is 25%. In some embodiments, a first threshold amount is 50%. In some embodiments, a first threshold amount is 70%. In some embodiments, a first threshold amount is 80%. In some embodiments, a first threshold amount is 90%. In some embodiments, a first threshold amount is 95%.
• the composition is characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.f. In some embodiments, the composition is characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.f. In some embodiments, the composition is characterized in that a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.f. In some embodiments, a first threshold amount is 25%. In some embodiments, a first threshold amount is 50%. In some embodiments, a first threshold amount is 70%. In some embodiments, a first threshold amount is 80%. In some embodiments, a first threshold amount is 90%. In some embodiments, a first threshold amount is 95%.
• the composition is characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.g. In some embodiments, the composition is characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.g. In some embodiments, the composition is characterized in that a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.g. In some embodiments, a first threshold amount is 12.5%. In some embodiments, a first threshold amount is 25%. In some embodiments, a first threshold amount is 50%. In some embodiments, a first threshold amount is 70%. In some embodiments, a first threshold amount is 80%. In some embodiments, a first threshold amount is 90%. In some embodiments, a first threshold amount is 95%.
• the composition is characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.h. In some embodiments, the composition is characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.h. In some embodiments, the composition is characterized in that a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.h. In some embodiments, a first threshold amount is 25%. In some embodiments, a first threshold amount is 50%. In some embodiments, a first threshold amount is 70%. In some embodiments, a first threshold amount is 80%. In some embodiments, a first threshold amount is 90%. In some embodiments, a first threshold amount is 95%.
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than or equal to a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of a first formula selected from formulae La, Lb.l, Lb.2, Lc, Ld, Le, Lf, Lg, and Lh; and
• a second threshold amount of the total amount of the chemical entities of the first formula in the composition are chemical entities of the same stereoisomer of the first formula.
• greater than a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of a first formula selected from formulae La, Lb.l, Lb.2, Lc, Ld, Le, Lf, Lg, and Lh.
• a first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of a first formula selected from formulae La, Lb.l, Lb.2, Lc, Ld, Le, Lf, Lg, and Lh.
• greater than a second threshold amount of the total amount of the chemical entities of the first formula in the composition are chemical entities of the same stereoisomer of the first formula.
• a second threshold amount of the total amount of the chemical entities of the first formula in the composition are chemical entities of the same stereoisomer of the first formula.
• a first formula is formula La.
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La, and greater than or equal to a second threshold amount of the total amount of the chemical entities of formula La in the composition are chemical entities of the same stereoisomer of formula La.
• a stereoisomer of formula La has the structure of formula I.a.i:
• a stereoisomer of formula La has the structure of formula
• a stereoisomer of formula La has the structure of formula I.a.iii:
• a stereoisomer of formula La has the structure of formula La.iv:
• a stereoisomer of formula La has the structure of formula
• a stereoisomer of formula La has the structure of formula I.a.vi:
• a stereoisomer of formula La has the structure of formula La.vii:
• a stereoisomer of formula La has the structure of formula
• a stereoisomer of formula La has the structure of formula La.ix:
• a stereoisomer of formula La has the structure of formula La.x:
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition are chemical entities of formula I.a.i. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition are chemical entities of formula I.a.ii. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition are chemical entities of formula I.a.iii. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition are chemical entities of formula La.iv.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition are chemical entities of formula La.v. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition are chemical entities of formula La.vi. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition are chemical entities of formula La.vii. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition are chemical entities of formula La.viii. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula La in the composition are chemical entities of formula La.ix.
• a first formula is formula I.b.l.
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.l, and greater than or equal to a second threshold amount of the total amount of the chemical entities of formula I.b.l in the composition are chemical entities of the same stereoisomer of formula I.b.l.
• a stereoisomer of formula I.b.l has the structure of formula Lb.l.i (i.e., R4-SS-cKK-E12).
• a stereoisomer of formula I.b.l has the structure of formula Lb.l.ii (i.e., S4-SS-cKK-E12).
• a stereoisomer of formula I.b.l has the structure of formula I.b.l.iii:
• a stereoisomer of formula I.b.l has the structure of formula I.b.l.iv:
• a stereoisomer of formula I.b.l has the structure of formula Lb.l.v:
• a stereoisomer of formula I.b.l has the structure of formula I.b.l.vi:
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.l in the composition are chemical entities of formula I.b.l.i. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.l in the composition are chemical entities of formula Lb.l.ii. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.l in the composition are chemical entities of formula I.b.l.iii. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.l in the composition are chemical entities of formula I.b.l.iv.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.l in the composition are chemical entities of formula I.b.l.v. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.l in the composition are chemical entities of formula I.b.l.vi.
• a first formula is formula Lb.2.
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula Lb.2, and greater than or equal to a second threshold amount of the total amount of the chemical entities of formula Lb.2 in the composition are chemical entities of the same stereoisomer of formula Lb.2.
• a stereoisomer of formula Lb.2 has the structure of formula I.b.2.i (i.e., R4-RR-cKK-E12).
• a stereoisomer of formula Lb.2 has the structure of formula I.b.2.ii (i.e., S4-RR-cKK-E12).
• a stereoisomer of formula Lb.2 has the structure of formula I.b.2.iii:
• a stereoisomer of formula Lb.2 has the structure of formula
• a stereoisomer of formula Lb.2 has the structure of formula I.b.2.v:
• a stereoisomer of formula Lb.2 has the structure of formula I.b.2.vi:
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula Lb.2 in the composition are chemical entities of formula I.b.2.i. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula Lb.2 in the composition are chemical entities of formula I.b.2.ii. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula Lb.2 in the composition are chemical entities of formula I.b.2.iii. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.2 in the composition are chemical entities of formula I.b.2.iv.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.2 in the composition are chemical entities of formula I.b.2.v. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.b.2 in the composition are chemical entities of formula I.b.2.vi.
• a first formula is formula I.c.
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.c, and greater than or equal to a second threshold amount of the total amount of the chemical entities of formula I.c in the composition are chemical entities of the same stereoisomer of formula I.c.
• a stereoisomer of formula I.c has the structure of formula I.a.i.
• a stereoisomer of formula I.c has the structure of formula I.b.l.i.
• a stereoisomer of formula I.c has the structure of formula I.b.2.i.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.c in the composition are chemical entities of formula I.a.i. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.c in the composition are chemical entities of formula I.b.l.i. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.c in the composition are chemical entities of formula I.b.2.i.
• a first formula is formula I.d.
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.d, and greater than or equal to a second threshold amount of the total amount of the chemical entities of formula I.d in the composition are chemical entities of the same stereoisomer of formula I.d.
• a stereoisomer of formula I.d has the structure of formula I.a.ii.
• a stereoisomer of formula I.d has the structure of formula I.b.l.ii.
• a stereoisomer of formula I.d has the structure of formula I.b.2.ii.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.d in the composition are chemical entities of formula I.a.ii. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.d in the composition are chemical entities of formula I.b.l.ii. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.d in the composition are chemical entities of formula I.b.2.ii.
• a first formula is formula I.e.
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.e, and greater than or equal to a second threshold amount of the total amount of the chemical entities of formula I.e in the composition are chemical entities of the same stereoisomer of formula I.e.
• a stereoisomer of formula I.e has the structure of formula I.a.iii.
• a stereoisomer of formula I.e has the structure of formula I.a.v.
• a stereoisomer of formula I.e has the structure of formula I.b.l.iii.
• a stereoisomer of formula I.e has the structure of formula I.b.2.iii.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.e in the composition are chemical entities of formula I.a.iii.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.e in the composition are chemical entities of formula I.a.v.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.e in the composition are chemical entities of formula I.b.l.iii.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.e in the composition are chemical entities of formula I.b.2.iii.
• a first formula is formula I.f.
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.f, and greater than or equal to a second threshold amount of the total amount of the chemical entities of formula I.f in the composition are chemical entities of the same stereoisomer of formula I.f.
• a stereoisomer of formula I.f has the structure of formula I.a.vii.
• a stereoisomer of formula I.f has the structure of formula I.a.ix.
• a stereoisomer of formula I.f has the structure of formula I.b.l.vi.
• a stereoisomer of formula I.f has the structure of formula I.b.2.vi.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.f in the composition are chemical entities of formula I.a.iii.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.f in the composition are chemical entities of formula I.a.ix.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.f in the composition are chemical entities of formula I.b.l.vi.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.f in the composition are chemical entities of formula I.b.2.vi.
• a first formula is formula I.g.
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.g, and greater than or equal to a second threshold amount of the total amount of the chemical entities of formula I.g in the composition are chemical entities of the same stereoisomer of formula I.g.
• a stereoisomer of formula I.g has the structure of formula I.a.iv.
• a stereoisomer of formula I.g has the structure of formula I.a.viii.
• a stereoisomer of formula I.g has the structure of formula I.b.l.iv.
• a stereoisomer of formula I.g has the structure of formula I.b.2.iv.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.g in the composition are chemical entities of formula I.a.iv.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.g in the composition are chemical entities of formula I.a.viii.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.g in the composition are chemical entities of formula I.b.l.iv.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.g in the composition are chemical entities of formula I.b.2.iv.
• a first formula is formula I.h.
• greater than or equal to the first threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.h, and greater than or equal to a second threshold amount of the total amount of the chemical entities of formula I.h in the composition are chemical entities of the same stereoisomer of formula I.h.
• a stereoisomer of formula I.h has the structure of formula I.a.vi.
• a stereoisomer of formula I.h has the structure of formula I.b.l.v.
• a stereoisomer of formula I.h has the structure of formula I.b.2.v.
• greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.h in the composition are chemical entities of formula I.a.vi. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.h in the composition are chemical entities of formula I.b.l.v. In some embodiments, greater than or equal to a second threshold amount of the total amount of chemical entities of formula I.h in the composition are chemical entities of formula I.b.2.v.
• the second threshold amount is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
• the second threshold amount is 50%>.
• the second threshold amount is 70%>.
• the second threshold amount is 80%>.
• the second threshold amount is 85%>.
• the second threshold amount is 90%>.
• the second threshold amount is 95%>.
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.
• a provided composition is characterized in that greater than a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I. In some embodiments, a provided composition is characterized in that a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.
• a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La, I.b.l, I.b.2, 1.c, I.d, I.e, I.f, I.g, or I.h.
• a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula La.
• a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.l.
• a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.2. In some embodiments, a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.e. In some embodiments, a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.d. In some embodiments, a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.e.
• a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.f. In some embodiments, a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.g. In some embodiments, a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.h.
• a provided composition is characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.a.i, I.a.ii, I.a.iii, I.a.iv, I.a.v, I.a.vi, I.a.vii, I.a.viii, I.a.ix, I.b.l.i, I.b.l.ii, I.b.l.iii, I.b.l.iv, I.b.l.v, I.b.l.vi, I.b.2.i, I.b.2.ii, I.b.2.iii, I.b.2.iv, I.b.2.v, and I.b.2.vi.
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than or equal to a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of the same stereoisomer of formula I.
• a provided composition is characterized in that greater than a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of the same stereoisomer of formula I. In some embodiments, a provided composition is characterized in that a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of the same stereoisomer of formula I.
• a stereoisomer of formula I has the structure of formula I.a.i, I.a.ii, I.a.iii, I.a.iv, I.a.v, I.a.vi, I.a.vii, I.a.viii, or I.a.ix.
• a stereoisomer of formula I has the structure of formula I.a.i.
• a stereoisomer of formula I has the structure of formula I.a.ii.
• a stereoisomer of formula I has the structure of formula I.a.iii.
• a stereoisomer of formula I has the structure of formula I.a.iv.
• a stereoisomer of formula I has the structure of formula I.a.v. In some embodiments, a stereoisomer of formula I has the structure of formula I.a.vi. In some embodiments, a stereoisomer of formula I has the structure of formula I.a.vii. In some embodiments, a stereoisomer of formula I has the structure of formula I.a.viii. In some embodiments, a stereoisomer of formula I has the structure of formula I.a.ix.
• a stereoisomer of formula I has the structure of formula I.b.l.i, I.b.l.ii, I.b.l.iii, I.b.l.iv, I.b.l.v, or I.b.l.vi.
• a stereoisomer of formula I has the structure of formula I.b.l.i.
• a stereoisomer of formula I has the structure of formula I.b.l.ii.
• a stereoisomer of formula I has the structure of formula I.b.l.iii.
• a stereoisomer of formula I has the structure of formula I.b.l.iv.
• a stereoisomer of formula I has the structure of formula I.b.l.v.
• a stereoisomer of formula I has the structure of formula I.b.l.vi.
• a stereoisomer of formula I has the structure of formula I.b.2.i, I.b.2.ii, I.b.2.iii, I.b.2.iv, I.b.2.v, or I.b.2.vi.
• a stereoisomer of formula I has the structure of formula I.b.2.i.
• a stereoisomer of formula I has the structure of formula I.b.2.ii.
• a stereoisomer of formula I has the structure of formula I.b.2.iii.
• a stereoisomer of formula I has the structure of formula I.b.2.iv.
• a stereoisomer of formula I has the structure of formula I.b.2.v.
• a stereoisomer of formula I has the structure of formula I.b.2.vi.
• the third threshold amount is 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% (w/w). In some embodiments, the third threshold amount is 50% (w/w). In some embodiments, the third threshold amount is 70% (w/w). In some embodiments, the third threshold amount is 80%> (w/w). In some embodiments, the third threshold amount is 85% (w/w). In some embodiments, the third threshold amount is 90%) (w/w). In some embodiments, the third threshold amount is 95%> (w/w). In some embodiments, the third threshold amount is 96% (w/w). In some embodiments, the third threshold amount is 97%> (w/w). In some embodiments, the third threshold amount is 98%> (w/w). In some embodiments, the third threshold amount is 99%> (w/w).
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.a.i:
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.a.ii:
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.l.i:
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.l.ii:
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.2.i:
• the present invention provides a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I:
• composition characterized in that greater than a third threshold amount of the total amount of chemical entities of formula I in the composition are chemical entities of formula I.b.2.ii:
• the second threshold amount is 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In some embodiments, the second threshold amount is 50%. In some embodiments, the second threshold amount is 70%. In some embodiments, the second threshold amount is 80%>. In some embodiments, the second threshold amount is 95%>.
• Liposomes for the Delivery of Agents Such as mRNA
• the present invention provides composition comprising a lipid compound described herein for delivery of therapeutic agents.
• a composition provided is a lipid based nanoparticle, such as a liposome.
• liposome refers to any lamellar, multilamellar, or solid lipid nanoparticle vesicle.
• a liposome as used herein can be formed by mixing one or more lipids or by mixing one or more lipids and polymer(s).
• liposome as used herein encompasses both lipid and polymer based nanoparticles.
• a liposome according to the present invention incorporates a lipid compound described herein as a cationic lipid component.
• a liposome according to the present invention includes a composition comprising one or more chemical entities of formula I.
• a suitable liposome may also contain second or additional cationic lipids, helper lipids (e.g., non-cationic lipids and/or cholesterol-based lipids), PEG-modified lipids, and/or polymers.
• cationic lipid(s) constitute(s) about 30-50%) (e.g., about 30-45%), about 30-40%), about 35-50%), about 35-45%), or about 35-40%>) of the liposome by molar ratio.
• the cationic lipid e.g., the composition comprising one or more chemical entities of formula I
• the liposome comprises a second lipid or additional cationic lipids.
• liposomes may comprise a second or additional cationic lipid.
• cationic lipid refers to any of a number of lipid species that have a net positive charge at a selected pH, such as physiological pH.
• Several cationic lipids have been described in the literature, many of which are commercially available.
• Particularly suitable cationic lipids for use in the compositions and methods of the invention include those described in international patent publications WO 2010/053572 (and particularly, C12-200 described at paragraph [00225]), WO 2012/170930 and WO 2013063468 each of which is incorporated herein by reference in its entirety.
• compositions and methods of the invention employ a lipid nanoparticles comprising an ionizable cationic lipid described in International Patent Application No. PCT/US2013/034602, filed March 29, 2013, Publ. No. WO 2013/149140 (incorporated herein by reference), such as, e.g, (15Z, 18Z)-N,N-dimethyl-6-(9Z, 12Z)-octadeca-9, 12-dien-l -yl)tetracosa- 15,18-dien- 1 -amine (HGT5000), ( 15Z, 18Z)-N,N- dimethyl-6-((9Z, 12Z)-octadeca-9, 12-dien- 1 -yl)tetracosa-4,15,18-trien-l -amine (HGT5001), and (15Z,18Z)-N,N-dimethyl-6-((9Z, 12Z)-octadeca-9, 12-dien- 1 -y
• the second or additional cationic lipid N-[l-(2,3- dioleyloxy)propyl]-N,N,N-trimethylammonium chloride or "DOTMA" is used.
• DOTMA cationic lipid N-[l-(2,3- dioleyloxy)propyl]-N,N,N-trimethylammonium chloride
• DOTMA can be formulated alone or can be combined with the neutral lipid, dioleoylphosphatidyl-ethanolamine or "DOPE" or other cationic or non-cationic lipids into a liposomal transfer vehicle or a lipid nanoparticle, and such liposomes can be used to enhance the delivery of nucleic acids into target cells.
• suitable cationic lipids include, for example, 5-carboxyspermylglycinedioctadecylamide or "DOGS,” 2,3-dioleyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-l-propanaminium or "DOSPA" (Behr et al. Proc.
• Additional exemplary cationic lipids also include l,2-distearyloxy-N,N-dimethyl-3-aminopropane or "DSDMA", l,2-dioleyloxy-N,N-dimethyl-3- aminopropane or "DODMA", 1 ,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane or "DLinDMA", l,2-dilinolenyloxy-N,N-dimethyl-3-aminopropane or "DLenDMA", N-dioleyl-N,N- dimethylammonium chloride or "DODAC", N,N-distearyl-N,N-dimethylarnrnonium bromide or "DDAB", N-(l,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide or "DMRIE", 3-dimethylamino-2-
• one or more of the cationic lipids comprise at least one of an imidazole, dialkylamino, or guanidinium moiety.
• the second or additional cationic lipid may be chosen from XTC (2,2-Dilinoleyl-4-dimethylaminoethyl-[l,3]-dioxolane), MC3 (((6Z,9Z,28Z,31Z)- heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate), ALNY-100 ((3aR,5s,6aS)- N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d] [1 ,3]dioxol- 5-amine)), NC98-5 (4,7, 13-tris(3-oxo-3-(undecylamino)propyl)-N 1 ,N16-diundecyl-4,7
• provided liposomes contain one or more non-cationic ("helper") lipids.
• non-cationic lipid refers to any neutral, zwitterionic or anionic lipid.
• anionic lipid refers to any of a number of lipid species that carry a net negative charge at a selected H, such as physiological pH.
• Non- cationic lipids include, but are not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N- maleimidomethyl)-cyclohexane-l-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl- ethanolamine
• non-cationic lipids may be used alone, but are preferably used in combination with other excipients, for example, cationic lipids.
• the non-cationic lipid may comprise a molar ratio of about 5% to about 90%, or about 10 % to about 70% of the total lipid present in a liposome.
• a non-cationic lipid is a neutral lipid, i.e., a lipid that does not carry a net charge in the conditions under which the composition is formulated and/or administered.
• the percentage of non- cationic lipid in a liposome may be greater than 5%, greater than 10%, greater than 20%, greater than 30%, or greater than 40%.
• provided liposomes comprise one or more cholesterol-based lipids.
• suitable cholesterol-based cationic lipids include, for example, DC-Choi (N,N-dimethyl-N-ethylcarboxamidocholesterol), l,4-bis(3-N-oleylamino-propyl)piperazine (Gao, et al. Biochem. Biophys. Res. Comm. 179, 280 (1991); Wolf et al. BioTechniques 23, 139 (1997); U.S. Pat. No. 5,744,335), or ICE.
• the cholesterol-based lipid may comprise a molar ration of about 2% to about 30%, or about 5% to about 20% of the total lipid present in a liposome. In some embodiments, The percentage of cholesterol-based lipid in the lipid nanoparticle may be greater than 5, %, 10%, greater than 20%, greater than 30%, or greater than 40%.
• provided liposomes comprise one or more PEGylated lipids.
• PEG polyethylene glycol
• derivatized lipids such as derivatized ceramides (PEG-CER), including N-Octanoyl-Sphingosine-1- [Succinyl(Methoxy Polyethylene Glycol)-2000] (C8 PEG-2000 ceramide) is also contemplated by the present invention in combination with one or more of the cationic and, in some embodiments, other lipids together which comprise the liposome.
• Contemplated PEG-modified lipids include, but are not limited to, a polyethylene glycol chain of up to 5 kDa in length covalently attached to a lipid with alkyl chain(s) of C6-C 20 length.
• a PEG- modified or PEGylated lipid is PEGylated cholesterol or PEG-2K.
• the addition of such components may prevent complex aggregation and may also provide a means for increasing circulation lifetime and increasing the delivery of the lipid-nucleic acid composition to the target cell, (Klibanov et al. (1990) FEBS Letters, 268 (1): 235-237), or they may be selected to rapidly exchange out of the formulation in vivo (see U.S. Pat. No. 5,885,613).
• particularly useful exchangeable lipids are PEG-ceramides having shorter acyl chains (e.g., C 14 or C 18 ).
• the PEG-modified phospholipid and derivitized lipids of the present invention may comprise a molar ratio from about 0% to about 15%, about 0.5%) to about 15%), about 1% to about 15%, about 4% to about 10%, or about 2% of the total lipid present in the liposome.
• the selection of second or additional cationic lipids, non-cationic lipids and/or PEG-modified lipids which comprise the lipid nanoparticle, as well as the relative molar ratio of such lipids to each other is based upon the characteristics of the selected lipid(s), the nature of the intended target cells, the characteristics of the mRNA to be delivered. Additional considerations include, for example, the saturation of the alkyl chain, as well as the size, charge, pH, pKa, fusogenicity and toxicity of the selected lipid(s). Thus the molar ratios may be adjusted accordingly. In some embodiments, the percentage of PEG- modified lipid in a liposome may be greater than 1%, greater than 2%, greater than 5%, greater than 10%, or greater than 15%.
• a suitable liposome according to the present invention further includes a polymer, in combination with one or more cationic lipids as described and, in some embodiments, other carriers including various lipids described herein.
• liposomal delivery vehicles as used herein, also encompass polymer containing nanoparticles.
• Suitable polymers may include, for example, polyacrylates, polyalkycyanoacrylates, polylactide, polylactide-polyglycolide copolymers, polycaprolactones, dextran, albumin, gelatin, alginate, collagen, chitosan, cyclodextrins, protamine, PEGylated protamine, PLL, PEGylated PLL and polyethylenimine (PEI).
• PEI polyethylenimine
• it may be branched PEI of a molecular weight ranging from 10 to 40 kDA, e.g., 25 kDa branched PEI (Sigma #408727).
• the present invention may be used to delivery any therapeutic agents.
• any therapeutic agents to be administered to a subject may be delivered using the complexes, picoparticles, nanoparticles, microparticles, micelles, or liposomes, described herein.
• the agent may be an organic molecule (e.g., a therapeutic agent, a drug), inorganic molecule, nucleic acid, protein, amino acid, peptide, polypeptide, polynucleotide, targeting agent, isotopically labeled organic or inorganic molecule, vaccine, immunological agent, etc.
• the agent to be delivered may be a mixture of agents.
• the therapeutic agents are organic molecules with pharmaceutical activity, e.g., a drug.
• the drug is an antibiotic, anti-viral agent, anesthetic, steroidal agent, anti-inflammatory agent, anti-neoplastic agent, anti-cancer agent, antigen, vaccine, antibody, decongestant, antihypertensive, sedative, birth control agent, progestational agent, anti-cholinergic, analgesic, anti-depressant, anti-psychotic, 13 -adrenergic blocking agent, diuretic, cardiovascular active agent, vasoactive agent, non-steroidal antiinflammatory agent, nutritional agent, etc.
• Diagnostic agents include gases; metals; commercially available imaging agents used in positron emissions tomography (PET), computer assisted tomography (CAT), single photon emission computerized tomography, x-ray, fluoroscopy, and magnetic resonance imaging (MRI); and contrast agents.
• PET positron emissions tomography
• CAT computer assisted tomography
• MRI magnetic resonance imaging
• suitable materials for use as contrast agents in MRI include gadolinium chelates, as well as iron, magnesium, manganese, copper, and chromium.
• Examples of materials useful for CAT and x-ray imaging include iodinebased materials.
• Therapeutic and prophylactic agents include, but are not limited to, antibiotics, nutritional supplements, and vaccines.
• Vaccines may comprise isolated proteins or peptides, inactivated organisms and viruses, dead organisms and viruses, genetically altered organisms or viruses, and cell extracts.
• the present invention may be used to deliver any polynucleotide.
• the polynucleotide is an interfering R A (R Ai).
• R Ai interfering R A
• the phenomenon of R Ai is discussed in greater detail, for example, in the following references: Elbashir et al, 2001, Genes Dev., 15: 188; Fire et al, 1998, Nature, 391 :806; Tabara et al, 1999, Cell, 99: 123; Hammond et al, Nature, 2000, 404:293; Zamore et al, 2000, Cell, 101 :25; Chakraborty, 2007, Curr. Drug Targets, 8:469; and Morris and Rossi, 2006, Gene Ther., 13:553.
• the polynucleotide is a dsRNA (double-stranded RNA). In certain embodiments, the polynucleotide is an siRNA (short interfering RNA). In certain embodiments, the polynucleotide is an shRNA (short hairpin RNA). In certain embodiments, the polynucleotide is an miRNA (micro RNA). Micro RNAs (miRNAs) are genomically encoded non-coding RNAs of about 21— 23 nucleotides in length that help regulate gene expression, particularly during development. See, e.g., Barrel, 2004, Cell, 116:281; Novina and Sharp, 2004, Nature, 430: 161; and U.S.
• miRNAs are genomically encoded non-coding RNAs of about 21— 23 nucleotides in length that help regulate gene expression, particularly during development. See, e.g., Barrel, 2004, Cell, 116:281; Novina and Sharp, 2004, Nature, 430: 161
• Patent Publication 2005/0059005 also reviewed in Wang and Li, 2007, Front. Biosci., 12:3975; and Zhao, 2007, Trends Biochem. Sci., 32: 189.
• the polynucleotide is an antisense RNA.
• the polynucleotide may be provided as an antisense agent or RNA interference (RNAi).
• RNAi RNA interference
• Antisense therapy is meant to include, e.g., administration or in situ provision of single- or double-stranded oligonucleotides or their derivatives which specifically hybridize, e.g., bind, under cellular conditions, with cellular mRNA and/or genomic DNA, or mutants thereof, so as to inhibit expression of the encoded protein, e.g., by inhibiting transcription and/or translation.
• Crooke Molecular mechanisms of action of antisense drugs" Biochim. Biophys.
• the binding may be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interactions in the major groove of the double helix (i.e., triple helix formation). See, e.g., Chan et al, J. Mol. Med. 75(4):267-282, 1997.
• dsR A, siRNA, shR A, miRNA, antisense RNA, and/or RNAi can be designed and/or predicted using one or more of a large number of available algorithms.
• the following resources can be utilized to design and/or predict polynucleotides: algorithms found at Alnylum Online, Dharmacon Online, OligoEngine Online, Molecula Online, Ambion Online, BioPredsi Online, RNAi Web Online, Chang Bioscience Online, Invitrogen Online, LentiWeb Online GenScript Online, Protocol Online; Reynolds et al, 2004, Nat.
• the polynucleotides may be of any size or sequence, and they may be single- or double-stranded. In certain embodiments, the polynucleotide is greater than 100 base pairs long. In certain embodiments, the polynucleotide is greater than 1000 base pairs long and may be greater than 10,000 base pairs long.
• the polynucleotide may be provided by any means known in the art. In certain embodiments, the polynucleotide has been engineered using recombinant techniques. See, e.g., Ausubel et al, Current Protocols in Molecular Biology (John Wiley & Sons, Inc., New York, 1999); Molecular Cloning: A Laboratory Manual, 2nd Ed., ed.
• the polynucleotide may also be obtained from natural sources and purified from contaminating components found normally in nature.
• the polynucleotide may also be chemically synthesized in a laboratory. In certain embodiments, the polynucleotide is synthesized using standard solid phase chemistry.
• the polynucleotide may be modified by chemical or biological means. In certain embodiments, these modifications lead to increased stability of the polynucleotide. Modifications include methylation, phosphorylation, end-capping, etc. mRNA
• the present invention can be used to deliver any mRNA.
• mRNA is typically thought of as the type of RNA that carries information from DNA to the ribosome.
• the existence of mRNA is usually very brief and includes processing and translation, followed by degradation.
• mRNA processing comprises the addition of a "cap” on the N-terminal (5') end, and a "tail” on the C-terminal (3') end.
• a typical cap is a 7-methylguanosine cap, which is a guanosine that is linked through a 5 '-5 '-triphosphate bond to the first transcribed nucleotide.
• the presence of the cap is important in providing resistance to nucleases found in most eukaryotic cells.
• the tail is typically a polyadenylation event whereby a polyadenylyl moiety is added to the 3' end of the mRNA molecule.
• the presence of this "tail” serves to protect the mRNA from exonuclease degradation.
• Messenger RNA typically is translated by the ribosomes into a series of amino acids that make up a protein.
• any mRNA capable of being translated into one or more peptides (e.g., proteins) or peptide fragments is contemplated as within the scope of the present invention.
• an mRNA encodes one or more naturally occurring peptides.
• an mRNA encodes one or more modified or non-natural peptides.
• an mRNA encodes an intracellular protein.
• an mRNA encodes a cytosolic protein.
• an mRNA encodes a protein associated with the actin cytoskeleton.
• an mRNA encodes a protein associated with the plasma membrane.
• an mRNA encodes a transmembrane protein.
• an mRNA encodes an ion channel protein.
• an mRNA encodes a perinuclear protein.
• an mRNA encodes a nuclear protein.
• an mRNA encodes a transcription factor.
• an mRNA encodes a chaperone protein.
• an mRNA encodes an intracellular enzyme (e.g., mRNA encoding an enzyme associated with urea cycle or lysosomal storage metabolic disorders).
• an mRNA encodes a protein involved in cellular metabolism, DNA repair, transcription and/or translation.
• an mRNA encodes an extracellular protein.
• an mRNA encodes a protein associated with the extracellular matrix.
• an mRNA encodes a secreted protein.
• an mRNA used in the composition and methods of the invention may be used to express functional proteins or enzymes that are excreted or secreted by one or more target cells into the surrounding extracellular fluid (e.g., mRNA encoding hormones and/or neurotransmitters).
• mRNAs according to the present invention may be synthesized according to any of a variety of known methods.
• mRNAs according to the present invention may be synthesized via in vitro transcription (IVT).
• IVT in vitro transcription
• IVT is typically performed with a linear or circular DNA template containing a promoter, a pool of ribonucleotide triphosphates, a buffer system that may include DTT and magnesium ions, and an appropriate RNA polymerase (e.g., T3, T7 or SP6 RNA polymerase), DNAse I, pyrophosphatase, and/or RNAse inhibitor.
• RNA polymerase e.g., T3, T7 or SP6 RNA polymerase
• a DNA template is transcribed in vitro.
• a suitable DNA template typically has a promoter, for example a T3, T7 or SP6 promoter, for in vitro transcription, followed by desired nucleotide sequence for desired mRNA and a termination signal.
• Desired mRNA sequence(s) according to the invention may be determined and incorporated into a DNA template using standard methods. For example, starting from a desired amino acid sequence (e.g., an enzyme sequence), a virtual reverse translation is carried out based on the degenerated genetic code. Optimization algorithms may then be used for selection of suitable codons. Typically, the G/C content can be optimized to achieve the highest possible G/C content on one hand, taking into the best possible account the frequency of the tRNAs according to codon usage on the other hand. The optimized RNA sequence can be established and displayed, for example, with the aid of an appropriate display device and compared with the original (wild-type) sequence. A secondary structure can also be analyzed to calculate stabilizing and destabilizing properties or, respectively, regions of the RNA.
• a desired amino acid sequence e.g., an enzyme sequence
• Optimization algorithms may then be used for selection of suitable codons.
• the G/C content can be optimized to achieve the highest possible G/C content on one hand, taking into the best possible account the frequency
• mRNA according to the present invention may be synthesized as unmodified or modified mRNA.
• mRNAs are modified to enhance stability.
• Modifications of mRNA can include, for example, modifications of the nucleotides of the RNA.
• An modified mR A according to the invention can thus include, for example, backbone modifications, sugar modifications or base modifications.
• mRNAs may be synthesized from naturally occurring nucleotides and/or nucleotide analogues (modified nucleotides) including, but not limited to, purines (adenine (A), guanine (G)) or pyrimidines (thymine (T), cytosine (C), uracil (U)), and as modified nucleotides analogues or derivatives of purines and pyrimidines, such as e.g.
• purines adenine (A), guanine (G)
• pyrimidines thymine (T), cytosine (C), uracil (U)
• modified nucleotides analogues or derivatives of purines and pyrimidines, such as e.g.
• mRNAs may contain RNA backbone modifications.
• a backbone modification is a modification in which the phosphates of the backbone of the nucleotides contained in the RNA are modified chemically.
• Exemplary backbone modifications typically include, but are not limited to, modifications from the group consisting of methylphosphonates, methylphosphoramidates, phosphoramidates, phosphorothioates (e.g. cytidine 5'-0-(l-thiophosphate)), boranophosphates, positively charged guanidinium groups etc., which means by replacing the phosphodiester linkage by other anionic, cationic or neutral groups.
• mR As (e.g., enzyme encoding mR As) may contain sugar modifications.
• a typical sugar modification is a chemical modification of the sugar of the nucleotides it contains including, but not limited to, sugar modifications chosen from the group consisting of 2'-deoxy-2'-fluoro-oligoribonucleotide (2'-fluoro-2'-deoxycytidine 5 '-triphosphate, 2'-fluoro-2'-deoxyuridine 5 '-triphosphate), 2'-deoxy-2'-deamine-oligoribonucleotide (2'-amino- 2'-deoxycytidine 5 '-triphosphate, 2'-amino-2'-deoxyuridine 5'-triphosphate), 2'-0-alkyloligoribo- nucleotide, 2'-deoxy-2'-C-alkyloligoribonucleotide (2'-0-methylcytidine 5 '-triphosphate, 2'
• mRNAs may contain modifications of the bases of the nucleotides (base modifications).
• base modifications A modified nucleotide which contains a base modification is also called a base-modified nucleotide.
• base- modified nucleotides include, but are not limited to, 2-amino-6-chloropurine riboside 5'-tri- phosphate, 2-aminoadenosine 5 '-triphosphate, 2-thiocytidine 5 '-triphosphate, 2-thiouridine 5 '-triphosphate, 4-thiouridine 5'-triphosphate, 5-aminoallylcytidine 5 '-triphosphate, 5-aminoallyl- uridine 5'-triphosphate, 5-bromocytidine 5 '-triphosphate, 5-bromouridine 5 '-triphosphate, 5-iodo- cytidine 5 '-triphosphate, 5-iodouridine 5 '-triphosphate, 5-methylcytidine 5 '-triphosphate,
• 6- chloropurine riboside 5 '-triphosphate 7-deazaadenosine 5'-triphosphate, 7-deazaguanosine 5'-triphosphate, 8-azaadenosine 5 '-triphosphate, 8-azidoadenosine 5 '-triphosphate, benzimidazole riboside 5 '-triphosphate, Nl-methyladenosine 5 '-triphosphate, Nl-methylguanosine 5 '-triphosphate, N6-methyladenosine 5 '-triphosphate, 06-methylguanosine 5 '-triphosphate, pseudo- uridine 5'-triphosphate, puromycin 5 '-triphosphate or xanthosine 5'-triphosphate.
• mRNA synthesis includes the addition of a "cap” on the N-terminal (5') end, and a “tail” on the C-terminal (3') end.
• the presence of the cap is important in providing resistance to nucleases found in most eukaryotic cells.
• the presence of a "tail” serves to protect the mRNA from exonuclease degradation.
• mR As e.g., enzyme encoding mRNAs
• a 5' cap is typically added as follows: first, an RNA terminal phosphatase removes one of the terminal phosphate groups from the 5' nucleotide, leaving two terminal phosphates; guanosine triphosphate (GTP) is then added to the terminal phosphates via a guanylyl transferase, producing a 5 '5 '5 triphosphate linkage; and the 7-nitrogen of guanine is then methylated by a methyltransferase.
• GTP guanosine triphosphate
• cap structures include, but are not limited to, m7G(5 * )ppp (5 * (A,G(5 * )ppp(5 * )A and G(5 * )ppp(5 * )G.
• naturally occurring cap structures comprise a 7-methyl guanosine that is linked via a triphosphate bridge to the 5'-end of the first transcribed nucleotide, resulting in a dinucleotide cap of m 7 G(5')ppp(5')N, where N is any nucleoside.
• the cap is added enzymatically. The cap is added in the nucleus and is catalyzed by the enzyme guanylyl transferase. The addition of the cap to the 5' terminal end of RNA occurs immediately after initiation of transcription.
• the terminal nucleoside is typically a guanosine, and is in the reverse orientation to all the other nucleotides, i.e., G(5')ppp(5')GpNpNp.
• a common cap for mRNA produced by in vitro transcription is m 7 G(5')ppp(5')G, which has been used as the dinucleotide cap in transcription with T7 or SP6 RNA polymerase in vitro to obtain RNAs having a cap structure in their 5'-termini.
• the prevailing method for the in vitro synthesis of capped mRNA employs a pre-formed dinucleotide of the form m 7 G(5')ppp(5')G ("m 7 GpppG”) as an initiator of transcription.
• ARCA Anti-Reverse Cap Analog
• modified ARCA which is generally a modified cap analog in which the 2' or 3' OH group is replaced with -OCH3.
• Additional cap analogs include, but are not limited to, chemical structures selected from the group consisting of m 7 GpppG, m 7 GpppA, m 7 GpppC; unmethylated cap analogs (e.g., GpppG); dimethylated cap analog (e.g., m 2 ' 7 GpppG), trimethylated cap analog (e.g.,
• m ' ' GpppG dimethylated symmetrical cap analogs (e.g., m Gpppm G), or anti reverse cap analogs (e.g., ARCA; m 7 , 2'0me GpppG, m 72'd GpppG, m 7 ' 3'0me GpppG, m 7 ' 3'd GpppG and their tetraphosphate derivatives) (see, e.g., Jemielity, J. et al, "Novel 'anti-reverse ' cap analogs with superior translational properties ' " , RNA, 9: 1108-1122 (2003)).
• ARCA m 7 , 2'0me GpppG, m 72'd GpppG, m 7 ' 3'0me GpppG, m 7 ' 3'd GpppG and their tetraphosphate derivatives
• a suitable cap is a 7-methyl guanylate ("m G") linked via a triphosphate bridge to the 5'-end of the first transcribed nucleotide, resulting in m 7 G(5')ppp(5')N, where N is any nucleoside.
• m G 7-methyl guanylate
• a preferred embodiment of a m 7 G cap utilized in embodiments of the invention is m 7 G(5')ppp(5')G.
• the cap is a CapO structure.
• CapO structures lack a 2'-0- methyl residue of the ribose attached to bases 1 and 2.
• the cap is a Capl structure.
• Capl structures have a 2'-0-methyl residue at base 2.
• the cap is a Cap2 structure.
• Cap2 structures have a 2'-0-methyl residue attached to both bases 2 and 3.
• m 7 G cap analogs are known in the art, many of which are commercially available. These include the m 7 GpppG described above, as well as the ARCA 3'-OCH 3 and 2'- OCH 3 cap analogs (Jemielity, J. et al., RNA, 9: 1108-1122 (2003)). Additional cap analogs for use in embodiments of the invention include N7-benzylated dinucleoside tetraphosphate analogs (described in Grudzien, E.
• a tail serves to protect the mRNA from exonuclease degradation.
• the poly A tail is thought to stabilize natural messengers and synthetic sense RNA. Therefore, in certain embodiments a long poly A tail can be added to an mRNA molecule thus rendering the RNA more stable.
• Poly A tails can be added using a variety of art-recognized techniques. For example, long poly A tails can be added to synthetic or in vitro transcribed RNA using poly A polymerase (Yokoe, et al. Nature Biotechnology. 1996; 14: 1252-1256). A transcription vector can also encode long poly A tails. In addition, poly A tails can be added by transcription directly from PCR products.
• Poly A may also be ligated to the 3' end of a sense RNA with RNA ligase (see, e.g., Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1991 edition)).
• mRNAs include a 3' poly(A) tail structure.
• the length of the poly A tail can be at least about 10, 50, 100, 200, 300, 400 at least 500 nucleotides.
• a poly-A tail on the 3' terminus of mRNA typically includes about 10 to 300 adenosine nucleotides (e.g., about 10 to 200 adenosine nucleotides, about 10 to 150 adenosine nucleotides, about 10 to 100 adenosine nucleotides, about 20 to 70 adenosine nucleotides, or about 20 to 60 adenosine nucleotides).
• mRNAs include a 3' poly(C) tail structure.
• a suitable poly-C tail on the 3' terminus of mRNA typically include about 10 to 200 cytosine nucleotides (e.g., about 10 to 150 cytosine nucleotides, about 10 to 100 cytosine nucleotides, about 20 to 70 cytosine nucleotides, about 20 to 60 cytosine nucleotides, or about 10 to 40 cytosine nucleotides).
• the poly-C tail may be added to the poly-A tail or may substitute the poly-A tail.
• the length of the poly A or poly C tail is adjusted to control the stability of a modified sense mRNA molecule of the invention and, thus, the transcription of protein.
• the length of the poly A tail can influence the half-life of a sense mRNA molecule, the length of the poly A tail can be adjusted to modify the level of resistance of the mRNA to nucleases and thereby control the time course of polynucleotide expression and/or polypeptide production in a target cell.
• mRNAs include a 5' and/or 3' untranslated region.
• a 5' untranslated region includes one or more elements that affect an mRNA's stability or translation, for example, an iron responsive element.
• a 5' untranslated region may be between about 50 and 500 nucleotides in length.
• a 3' untranslated region includes one or more of a polyadenylation signal, a binding site for proteins that affect an mRNA's stability of location in a cell, or one or more binding sites for miRNAs.
• a 3' untranslated region may be between 50 and 500 nucleotides in length or longer.
• Exemplary 3' and/or 5' UTR sequences can be derived from mRNA molecules which are stable (e.g., globin, actin, GAPDH, tubulin, histone, or citric acid cycle enzymes) to increase the stability of the sense mRNA molecule.
• a 5' UTR sequence may include a partial sequence of a CMV immediate-early 1 (IE1) gene, or a fragment thereof to improve the nuclease resistance and/or improve the half-life of the polynucleotide.
• IE1 immediate-early 1
• hGH human growth hormone
• modifications improve the stability and/or pharmacokinetic properties (e.g., half-life) of the polynucleotide relative to their unmodified counterparts, and include, for example modifications made to improve such polynucleotides' resistance to in vivo nuclease digestion.
• any size mRNA may be encapsulated by provided liposomes.
• the provided liposomes may encapsulate mRNA of greater than about 0.5 kb, 1 kb, 1.5 kb, 2 kb, 2.5 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, or 5 kb in length.
• the liposomes for use in provided compositions can be prepared by various techniques which are presently known in the art.
• multilamellar vesicles may be prepared according to conventional techniques, such as by depositing a selected lipid on the inside wall of a suitable container or vessel by dissolving the lipid in an appropriate solvent, and then evaporating the solvent to leave a thin film on the inside of the vessel or by spray drying. An aqueous phase may then added to the vessel with a vortexing motion which results in the formation of MLVs.
• Uni-lamellar vesicles UUV
• unilamellar vesicles can be formed by detergent removal techniques.
• compositions comprise a liposome wherein an agent, such as a nucleic acid e.g., mRNA, is associated on both the surface of the liposome and encapsulated within the same liposome.
• an agent such as a nucleic acid e.g., mRNA
• cationic liposomes may associate with the mRNA through electrostatic interactions.
• cationic liposomes may associate with the mRNA through electrostatic interactions.
• the compositions and methods of the invention comprise mRNA encapsulated in a liposome.
• the one or more mRNA species may be encapsulated in the same liposome.
• the one or more mRNA species may be encapsulated in different liposomes.
• the mRNA is encapsulated in one or more liposomes, which differ in their lipid composition, molar ratio of lipid components, size, charge (Zeta potential), targeting ligands and/or combinations thereof.
• the one or more liposome may have a different composition of cationic lipids, neutral lipid, PEG-modified lipid and/or combinations thereof.
• the one or more lipisomes may have a different molar ratio of cationic lipid, neutral lipid, cholesterol and PEG-modified lipid used to create the liposome.
• a desired therapeutic agent such as a nucleic acid (e.g., mR A)
• a desired therapeutic agent such as a nucleic acid (e.g., mR A)
• loading Exemplary methods are described in Lasic, et al, FEBS Lett., 312: 255-258, 1992, which is incorporated herein by reference.
• the liposome -incorporated nucleic acids may be completely or partially located in the interior space of the liposome, within the bilayer membrane of the liposome, or associated with the exterior surface of the liposome membrane.
• the incorporation of a nucleic acid into liposomes is also referred to herein as "encapsulation" wherein the nucleic acid is entirely contained within the interior space of the liposome.
• a suitable delivery vehicle is capable of enhancing the stability of the mRNA contained therein and/or facilitate the delivery of mRNA to the target cell or tissue.
• Suitable liposomes in accordance with the present invention may be made in various sizes.
• provided liposomes may be made smaller than previously known mRNA encapsulating liposomes.
• decreased size of liposomes is associated with more efficient delivery of mRNA. Selection of an appropriate liposome size may take into consideration the site of the target cell or tissue and to some extent the application for which the liposome is being made.
• an appropriate size of liposome is selected to facilitate systemic distribution of antibody encoded by the mRNA.
• a liposome may be sized such that its dimensions are smaller than the fenestrations of the endothelial layer lining hepatic sinusoids in the liver; in such cases the liposome could readily penetrate such endothelial fenestrations to reach the target hepatocytes.
• a liposome may be sized such that the dimensions of the liposome are of a sufficient diameter to limit or expressly avoid distribution into certain cells or tissues.
• a liposome may be sized such that its dimensions are larger than the fenestrations of the endothelial layer lining hepatic sinusoids to thereby limit distribution of the liposomes to hepatocytes.
• a suitable liposome has a size of or less than about 500 nm, 450 nm, 400 nm, 350 nm, 300 nm, 250 nm, 200 nm, 150 nm, 125 nm, 110 nm, 100 nm, 95 nm, 90 nm, 85 nm, 80 nm, 75 nm, 70 nm, 65 nm, 60 nm, 55 nm, or 50 nm.
• a suitable liposome has a size no greater than about 250 nm (e.g., no greater than about 225 nm, 200 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, or 50 nm). In some embodiments, a suitable liposome has a size ranging from about 10 - 250 nm (e.g., ranging from about 10 - 225 nm, 10 - 200 nm, 10 - 175 nm, 10 - 150 nm, 10 - 125 nm, 10 - 100 nm, 10 - 75 nm, or 10 - 50 nm).
• a suitable liposome has a size ranging from about 100 - 250 nm (e.g., ranging from about 100 - 225 nm, 100 - 200 nm, 100 - 175 nm, 100 - 150 nm). In some embodiments, a suitable liposome has a size ranging from about 10 - 100 nm (e.g., ranging from about 10 - 90 nm, 10 - 80 nm, 10 - 70 nm, 10 - 60 nm, or 10 - 50 nm).
• a variety of alternative methods known in the art are available for sizing of a population of liposomes.
• One such sizing method is described in U.S. Pat. No. 4,737,323, incorporated herein by reference. Sonicating a liposome suspension either by bath or probe sonication produces a progressive size reduction down to small ULV less than about 0.05 microns in diameter.
• Homogenization is another method that relies on shearing energy to fragment large liposomes into smaller ones. In a typical homogenization procedure, MLV are recirculated through a standard emulsion homogenizer until selected liposome sizes, typically between about 0.1 and 0.5 microns, are observed.
• the size of the liposomes may be determined by quasi-electric light scattering (QELS) as described in Bloomfield, Ann. Rev. Biophys. Bioeng., 10:421-150 (1981), incorporated herein by reference. Average liposome diameter may be reduced by sonication of formed liposomes. Intermittent sonication cycles may be alternated with QELS assessment to guide efficient liposome synthesis.
• QELS quasi-electric light scattering
• delivery vehicles such as liposomes can be formulated in combination with one or more additional nucleic acids, carriers, targeting ligands or stabilizing reagents, or in pharmacological compositions where it is mixed with suitable excipients.
• Provided liposomally-encapsulated agents such as a nucleic acid e.g., mRNA and compositions containing the same, may be administered and dosed in accordance with current medical practice, taking into account the clinical condition of the subject, the site and method of administration, the scheduling of administration, the subject's age, sex, body weight and other factors relevant to clinicians of ordinary skill in the art.
• the "effective amount" for the purposes herein may be determined by such relevant considerations as are known to those of ordinary skill in experimental clinical research, pharmacological, clinical and medical arts.
• the amount administered is effective to achieve at least some stabilization, improvement or elimination of symptoms and other indicators as are selected as appropriate measures of disease progress, regression or improvement by those of skill in the art.
• a suitable amount and dosing regimen is one that causes at least transient protein ⁇ e.g. , enzyme) production.
• Suitable routes of administration include, for example, oral, rectal, vaginal, transmucosal, pulmonary including intratracheal or inhaled, or intestinal administration; parenteral delivery, including intradermal, transdermal (topical), intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, and/or intranasal administration.
• liposomally encapsulated agents such as a nucleic acid e.g., mRNA and compositions of the invention may be administered in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a targeted tissue, preferably in a sustained release formulation. Local delivery can be affected in various ways, depending on the tissue to be targeted.
• compositions of the present invention can be inhaled (for nasal, tracheal, or bronchial delivery); compositions of the present invention can be injected into the site of injury, disease manifestation, or pain, for example; compositions can be provided in lozenges for oral, tracheal, or esophageal application; can be supplied in liquid, tablet or capsule form for administration to the stomach or intestines, can be supplied in suppository form for rectal or vaginal application; or can even be delivered to the eye by use of creams, drops, or even injection.
• Formulations containing provided compositions complexed with therapeutic molecules or ligands can even be surgically administered, for example in association with a polymer or other structure or substance that can allow the compositions to diffuse from the site of implantation to surrounding cells. Alternatively, they can be applied surgically without the use of polymers or supports.
• provided liposomes and/or compositions are formulated such that they are suitable for extended-release of the agent, e.g., mRNA contained therein.
• extended-release compositions may be conveniently administered to a subject at extended dosing intervals.
• the compositions of the present invention are administered to a subject twice day, daily or every other day.
• the compositions of the present invention are administered to a subject twice a week, once a week, every ten days, every two weeks, every three weeks, or more preferably every four weeks, once a month, every six weeks, every eight weeks, every other month, every three months, every four months, every six months, every eight months, every nine months or annually.
• compositions and liposomes which are formulated for depot administration (e.g., intramuscularly, subcutaneously, intravitreally) to either deliver or release a mRNA over extended periods of time.
• depot administration e.g., intramuscularly, subcutaneously, intravitreally
• the extended-release means employed are combined with modifications made to the mRNA to enhance stability.
• lyophilized pharmaceutical compositions comprising one or more of the liposomes disclosed herein and related methods for the use of such compositions as disclosed for example, in International Patent Application No. PCT/US2012/041663, filed June 8, 2012, Publ. No. WO 2012/170889, the teachings of which are incorporated herein by reference in their entirety.
• lyophilized pharmaceutical compositions according to the invention may be reconstituted prior to administration or can be reconstituted in vivo.
• a lyophilized pharmaceutical composition can be formulated in an appropriate dosage form (e.g., an intradermal dosage form such as a disk, rod or membrane) and administered such that the dosage form is rehydrated over time in vivo by the individual's bodily fluids.
• an appropriate dosage form e.g., an intradermal dosage form such as a disk, rod or membrane
• Provided liposomes and compositions may be administered to any desired tissue.
• the agent e.g., mRNA delivered by provided liposomes or compositions is expressed in the tissue in which the liposomes and/or compositions were administered.
• the mRNA delivered is expressed in a tissue different from the tissue in which the liposomes and/or compositions were administered
• Exemplary tissues in which delivered mRNA may be delivered and/or expressed include, but are not limited to the liver, kidney, heart, spleen, serum, brain, skeletal muscle, lymph nodes, skin, and/or cerebrospinal fluid.
• the timing of expression of delivered agents can be tuned to suit a particular medical need.
• the expression of the protein encoded by delivered mRNA is detectable 1, 2, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, and/or 72 hours in serum or target tissues after a single administration of provided liposomes or compositions.
• the expression of the protein encoded by the mRNA is detectable 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, and/or 7 days in serum or target tissues after a single administration of provided liposomes or compositions.
• the expression of the protein encoded by the mRNA is detectable 1 week, 2 weeks, 3 weeks, and/or 4 weeks in serum or target tissues after a single administration of provided liposomes or compositions. In some embodiments, the expression of the protein encoded by the mRNA is detectable after a month or longer after a single administration of provided liposomes or compositions.
• Racemic compound 10 was prepared from protected lysine derivative 1, Boc-Lys(Z)- OSu, by cleavage of the alpha-amino tert-butyl carbamate with trifluoroacetic acid and dimerization of the resulting free amine to form 3,6-dioxopiperazine 2. Hydrogenation of 2 over catalytic palladium yields primary diamine 3, which is treated with four equivalents of epoxide 4 and triethylamine to form the racemic 3,6-dioxopiperazine 10 of formula I.
• Chiral compound 10 was synthesized via N-alkylation of protected lysine derivative 5 with two equivalents of epoxide 4 to form diol 6. Hydrogenation of diol 6 over catalytic palladium forms alpha amino acid 7, which is divided into two portions. The first portion of alpha amino acid 7 has its alpha amino group protected as the tert-butyl carbamate, upon treatment with Boc anhydride, to form carboxylic acid 8. The second portion of alpha amino acid 7 has its free acid converted to the methyl ester to form amine 9.
• Carboxylic acid 8 and amine 9 are coupled to an amide intermediate via peptide coupling reagents such as HATU and diethanolamine in aprotic solvent such as DMF, the tert-butyl carbamate group of the amide intermediate is cleaved with trifluoroacetic acid in dichloromethane, and the resulting amino ester product is cyclized to the piperazine-2,5-dione 10.
• peptide coupling reagents such as HATU and diethanolamine in aprotic solvent such as DMF
• aprotic solvent such as DMF
• the tert-butyl carbamate group of the amide intermediate is cleaved with trifluoroacetic acid in dichloromethane
• the resulting amino ester product is cyclized to the piperazine-2,5-dione 10.
• the stereochemistry at all chiral centers is preserved via this route.
• Example 3 The compound of Formula I.a.i (i.e., R4-SR-cKK-E12)
• Method B To a suspension of 8.1 (50 g, 0.2 mol) in MeOH (600 mL) was added DIPEA (45 mL), then compound 5.1 (150 g, 0.813 mol, 4.0 equiv) was added. The reaction mixture was stirred at room temperature for 7 days. Solvents were removed, the residue was purified by column (1.0 kg of Si0 2 , eluted with 0 - 30% MeOH in EtOAc) to give 9.1 as a waxy solid (83 g, 67%).
• the impure R4-SR- CKK-E12 was re-purified by column to give 12 g of pure R4-SR- CKK-E12. Thus, a total 46 g (55%) of pure R4-SR- CKK-E12 (gummy solid) was obtained.
• Example 4 The compound of Formula I.aAi (i.e., S4-SR-cKK-E12)
• Example 5 The compound of Formula I.b.l.i (i.e., R4-SS-cKK-E12)
• Example 6 The compound of Formula I.b.l.ii (i.e., S4-SS-cKK-E12)
• the resulting mixture was allowed to warm up to room temperature and stirred for 45 min. TFA was then removed and DCM (120 ml) was added to the residue, and then co-evaporated to remove residual TFA.
• the crude 5.4 was dissolved in anhydrous pyridine (1.6 L) at 0 0 C under N 2 , and the resulting mixture was stirred at room temperature overnight. The pyridine was then removed by rotavap, and the residue was diluted with diethyl ether (1 L). The white solid formed was removed by filtration and washed with diethyl ether (200 ml).
• Example 7 The compound of Formula I.b.2.i (i.e., R4-RR-cKK-E12)
• Example 8 The compound of Formula I.b.2.ii (i.e., S4-RR-cKK-E12)
• the formulations described herein consisted of a multi-component lipid mixture of varying ratios employing one or more cationic lipids, helper lipids and PEGylated lipids designed to encapsulate various nucleic acid-based materials.
• the cationic lipid utilized throughout is the compound of formula I (3,6-bis(4-(bis(2- hydroxydodecyl)amino)butyl)piperazine-2,5-dione).
• Helper lipids can include (but not exclusively) DSPC (l,2-distearoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn- glycero-3-phosphocholine), DOPE (l,2-dioleyl-sn-glycero-3-phosphoethanolamine), DOPC (1 ,2-dioleyl-sn-glycero-3-phosphotidylcholine) DPPE (1 ,2-dipalmitoyl-sn-glycero-3- phosphoethanolamine), DMPE (l,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DOPG (,2- dioleoyl-5/7-glycero-3-phospho-(l'-rac-glycerol)), cholesterol, etc.
• the PEGylated lipids can include (but not exclusively) a poly(ethylene) glycol chain of up to 5 kDa in length covalently
• FIX Human Factor IX
• FTL codon-optimized Firefly Luciferase
• ASS1 codon- optimized human argininosuccinate synthetase
• Example 10 Analysis of ASSl protein produced via intravenously delivered ASSl mRNA- loaded nanoparticles:
• liver, spleen, kidney and heart of each mouse was harvested, apportioned into separate parts, and stored in either 10% neutral buffered formalin or snap-frozen and stored at - 80°C for analysis.
• Human ASS I ELISA Standard ELISA procedures were followed employing mouse anti-ASSl 2D1-2E12 IgG as the capture antibody with rabbit anti-ASSl #3285 IgG as the secondary (detection) antibody (Shire Human Genetic Therapies). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG was used for activation of the 3,3',5,5'- tetramethylbenzidine (TMB) substrate solution. The reaction was quenched using 2N H 2 S0 4 after 20 minutes. Detection was monitored via absorption (450 nm) on a Molecular Device SpectraMax instrument. Untreated mouse serum and organs and human ASS1 protein were used as negative and positive controls, respectively.
• HRP horseradish peroxidase
• TMB 3,3',5,5'- tetramethylbenzidine
• FIG. 1 depicts the amount of human ASSl protein detected via ELISA when treating mice human ASSl mRNA-loaded lipid nanoparticles, with various racemic and chiral compounds of formula I, at 1.0 mg/kg doses. The mice were sacrificed twenty-four hours post-injection and organs, such as livers, were harvested.
• ALT and AST alanine aminotransferase
• AST aspartate aminotransferase
• Increased expression levels of AST and/or ALT generally caused by agents that cause liver toxicity.
• the chiral compounds of formula I generally yielded lower expression levels of ALT and/or AST, i.e., correlating to lower liver toxicity issues, compared to stereochemically non-enriched, or stereochemically less enriched, compositions of the same lipid. See Tables 1 and 2 below.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Molecular Biology (AREA)
• Dispersion Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biochemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Biophysics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Physics & Mathematics (AREA)
• Biomedical Technology (AREA)
• Nanotechnology (AREA)
• Optics & Photonics (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Peptides Or Proteins (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Priority Applications (20)

Applications Claiming Priority (2)

Publications (1)

Family

ID=54929772

Family Applications (1)

Country Status (17)

Cited By (16)

Families Citing this family (11)

Citations (31)

Family Cites Families (303)

• 2015
  • 2015-06-24 EP EP15811080.9A patent/EP3160959B1/en active Active
  • 2015-06-24 ES ES15811080T patent/ES2964588T3/es active Active
  • 2015-06-24 SG SG11201610670WA patent/SG11201610670WA/en unknown
  • 2015-06-24 MX MX2017000143A patent/MX389802B/es unknown
  • 2015-06-24 CN CN202010289575.5A patent/CN111588695A/zh active Pending
  • 2015-06-24 MA MA040241A patent/MA40241A/fr unknown
  • 2015-06-24 PE PE2016002773A patent/PE20171238A1/es not_active Application Discontinuation
  • 2015-06-24 CN CN202211265951.2A patent/CN116059170A/zh active Pending
  • 2015-06-24 WO PCT/US2015/037392 patent/WO2015200465A1/en not_active Ceased
  • 2015-06-24 KR KR1020237008910A patent/KR102559979B1/ko active Active
  • 2015-06-24 CN CN201580043663.4A patent/CN106795142B/zh active Active
  • 2015-06-24 EA EA201692309A patent/EA033966B1/ru not_active IP Right Cessation
  • 2015-06-24 JP JP2016575045A patent/JP6599373B2/ja active Active
  • 2015-06-24 CA CA2952824A patent/CA2952824C/en active Active
  • 2015-06-24 UA UAA201612749A patent/UA121863C2/uk unknown
  • 2015-06-24 KR KR1020177000718A patent/KR102387898B1/ko active Active
  • 2015-06-24 AU AU2015279968A patent/AU2015279968B2/en active Active
  • 2015-06-24 US US14/749,027 patent/US10138213B2/en active Active
  • 2015-06-24 KR KR1020227012131A patent/KR102511554B1/ko active Active
• 2016
  • 2016-12-18 IL IL249615A patent/IL249615A0/en unknown
  • 2016-12-20 CL CL2016003263A patent/CL2016003263A1/es unknown
• 2017
  • 2017-01-04 MX MX2022001291A patent/MX2022001291A/es unknown
  • 2017-01-04 MX MX2022001292A patent/MX2022001292A/es unknown
• 2018
  • 2018-11-01 US US16/178,142 patent/US11104652B2/en active Active
• 2020
  • 2020-01-23 AU AU2020200489A patent/AU2020200489B2/en active Active
• 2021
  • 2021-03-02 AU AU2021201357A patent/AU2021201357B2/en active Active
  • 2021-07-22 US US17/382,757 patent/US20220048867A1/en not_active Abandoned
• 2023
  • 2023-03-16 AU AU2023201655A patent/AU2023201655A1/en not_active Abandoned
• 2024
  • 2024-09-20 US US18/890,983 patent/US20250145577A1/en active Pending

Patent Citations (33)

Non-Patent Citations (42)

Also Published As